Φορτώνει......
Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma
To overcome radioresistance in the treatment of osteosarcoma, a primary malignant tumor of the bone, radiotherapy is generally combined with radiosensitizers. The purpose of this study was to investigate a third-generation bisphosphonate, zoledronic acid (ZOL), as a radiosensitizer for osteosarcoma....
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Oncotarget |
|---|---|
| Κύριοι συγγραφείς: | , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Impact Journals LLC
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5342595/ https://ncbi.nlm.nih.gov/pubmed/27765919 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12281 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|